Study 2019-01 (HTA) Cost-effectiveness of a new vaccine against Herpes Zoster (Shingrix®)

Ongoing study - The aim of this project is to assess the efficacy, safety, and cost-effectiveness of a new vaccine (recombinant, adjuvanted) against Herpes Zoster (Shingrix®).

Published on: 
2019/09/02